July 26, 2018 First-ever biomarker qualified for Parkinson’s is a vital step toward improved clinical trials FOR IMMEDIATE RELEASE Contact: Kissy Black 615.298.1144 kissyblack@lotosnile.com Tucson, AZ — July 26, 2018 – The Criti
May 18, 2018 “Improving Clinical Trials to Deliver Better Treatments,” as featured in the Spring 2018 edition of “Progress, the research magazine of Parkinson’s UK”
May 7, 2018 C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) TUCSON, Ariz. – May 7, 2018 — Critical Path Institute‘s (C-Path) Patient-Reported Outcome (PRO) Consortium annou
April 26, 2018 CPTR Newsletter – April 2018 CPTR Newsletter – April 2018 In this issue: ReSeqTB to be Adopted for WHO Surveillance of Drug-Resistant TB New Collabora
April 16, 2018 Helmsley Charitable Trust Awards Critical Path Institute a Grant to Focus on Crohn’s Disease Biomarkers Tucson, AZ, and New York, NY – April 16, 2018 — The Leona M. and Harry B. Helmsley Charitable Trust has awarded Critical Path
February 12, 2018 Tucson-based Critical Path Institute emerging as top drug-research organization President and CEO Dr. Martha Brumfield was recently interviewed by the Arizona Daily Star for a profile on C-Path published Februa
February 5, 2018 Critical Path to TB Drug Regimens (CPTR) 2018 Annual Workshop, postponed Critical Path Institute and Bill & Melinda Gates Foundation have decided to postpone the Critical Path to TB Drug Regimens Wor
October 24, 2017 US FDA Awards I-ACT for Children a Grant for Pediatric Medicines and Devices Network
October 9, 2017 Critical Path Innovation Meeting On September 14, 2017, Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium and Electronic Patient-Repor